Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Sponsored Content | Blog | Greg Freiherr, Industry Consultant | PET Imaging | December 11, 2018

Digital Technology Pushes PET In New and Old Directions

A 90-second brain acquisition with FDG radiotracer — comparison of digital (Vereos, left, 1 mm) and conventional (Gemini TF, 4 mm) images.

A 90-second brain acquisition with FDG radiotracer — comparison of digital (Vereos, left, 1 mm) and conventional (Gemini TF, 4 mm) images.

Digital technology is opening remarkable opportunities for clinical positron emission tomography (PET) about which research is only beginning to hint.

“Twenty years ago we were excited that we could see a lesion. Now we want to understand its underlying biologic heterogeneity,” said Michael Knopp, M.D., a radiology professor at Ohio State University whose research with Philips’ digital PET/CT, called Vereos, is exploring applications within and beyond traditional clinical areas.

The digital technology underlying Vereos can provide the details that may escape analog systems, said Piotr Maniawski, director of clinical science for nuclear medicine at Philips Healthcare. Visualization using 4 mm cubes, which are typically delivered by analog systems, makes small lesions look spherical, he said. The very small voxels in digital images better visualize shapes and texture.

“Seeing if the texture is changing helps characterize the lesion,” said the Philips clinical director. The metabolism inside the lesion, he said, may be much different, depending on the location.

In a paper published May 2017 in the journal Contrast Media and Molecular Imaging, Knopp, who is the Novartis chair of Imaging Research at Ohio State University, and colleagues at Ohio State summarized how digital PET enables advanced functional tumor imaging.

 

A Digital Twist

Much like radiography began, PET started as an analog modality. Instead of film, PET relied on photomultiplier tubes (PMTs). In analog systems, light generated by a single scintillating crystal is channeled to multiple PMTs. In Vereos, light generated by a single scintillating crystal is channeled to its own detector.

Vereos’ digital detection is built on digital photon counting (DPC) technology, whereby crystals and sensors are coupled “one-to-one,” said Maniawski, who has worked with Knopp and others to assess the clinical capabilities conferred by Vereos’ digital technology. Light flashes produced by specific crystals are channeled directly to individual digital sensors. In stark contrast to analog technology, which accumulates signals from light flashes in analog detectors until reaching trigger points, “there is no light sharing,” Maniawski said. “The moment the detector registers this light, we know precisely which crystal produced it.”

Reconstruction algorithms onboard Vereos mathematically reconstruct digital PET into detailed images. These appear “more rich and precise” than those made using analog-based PET systems, Knopp said, due to the increased density of the data. The OSU researcher likened the benefit of data density to the improvement of smartphone images as those pictures gain more data density.

“When you pull up Google maps, the picture might look fuzzy at first and then as the data come in, it will look sharp and brilliant,” Knopp said. “This happens because the data density changes.”

Maniawski explained that voxels in Vereos images are densified with data collected by the 23,000 solid-state sensors from individual scintillation events. This added data density allows Vereos to package data into voxel volumes of 2 mm — or even 1 mm — cubes. This data density gives shape and texture to structures in the images.

 

Bringing Together Old and New

The game-changing appearance of Vereos’ images can be challenging, Knopp noted.

Because digital images show more detail, they may show lesions and features that might not be seen with analog technology. When comparing current digital images to past analog ones, the question arises: Were lesions now visible not seen previously because the technology could not see them? Or have they just recently occurred?

The answers to these questions can directly impact the management of patients being monitored for disease recurrence.

To deal with this incompatibility, Philips offers a feature in Vereos that reconstructs digital data as if they were acquired on an analog system. This is done with reconstruction algorithms, Maniawski said. These algorithms harmonize the digital data.

Vereos users who choose this option “end up with two images from the same data — a conventional looking image and a digital one,” Maniawski said.

Vereos can create a still picture and visualize changes over time. In the mid- to late-1980s, early developers of PET often acquired data dynamically. Serial acquisitions came into vogue when PET/CT imaging entered the mainstream. But dynamic imaging, similar to short video clips, can provide clinical information not found in static images.

Editor’s Note: This is the fifth in a series of blogs on the advances of digital PET/CT. The first is entitled How Digital PET/CT Can Improve Clinical Care; the second Why – And How – Digital PET Is Better Than Analog; the third Digital PET Balances Scan Time and Resolution; the fourth What Precision Means To PET

 

Related Content:

SPECIAL SUPPLEMENT: Examining the Value of Digital PET/CT

Related Content

Indeterminate lesion on PET/CT classified by PET/MRI for 53-y-old man with lung cancer.

Indeterminate lesion on PET/CT classified by PET/MRI for 53-y-old man with lung cancer. Contrast-enhanced CT (A), PET (B), and fused 18F-FDG PET/CT (C) images are displayed in comparison with contrast-enhanced T1-weighted MRI (D), PET, and fused 18F-FDG PET/MRI (F) images. In CT (A), hyperdense, subcentimeter liver lesion (arrows) in segment VII is suggestive of transient hepatic attenuation difference or small hemangioma. As malignancy cannot be excluded, it needs further investigation. On PET/MRI, lesion is clearly classified as metastasis because of contrast enhancement and tracer uptake due to later acquisition time point. Follow-up CT confirmed diagnosis after 78 d. Images created by Ole Martin, University Dusseldorf, Medical Faculty and Benedikt Schaarschmidt, University Hospital Essen.

News | PET-MRI | September 18, 2020
September 18, 2020 — A single-center observational study of more than 1,000 oncological examinations has demonstrated
HABLE study prioritizes brain imaging and biomarker research among Mexican Americans.

Getty Images

News | PET Imaging | September 14, 2020
September 14, 2020 — To meet the pressing need to better understand the prevalence, progression, and clinical impact
A 12-year-long collaboration with Canon Medical Research USA, Canon Medical Systems Japan and Southern Nevada outpatient radiology leader Steinberg Diagnostic Medical Imaging (SDMI) has resulted in the development of 3 PET scanners, each generation more advanced than the last
News | PET-CT | September 08, 2020
September 8, 2020 — A 12-year-long collaboration with...
a) Includes scintigraphy and PET with and without concomitant CT. b) Includes conventional radiography, dual-energy x-ray absorptiometry, fluoroscopy, and radiography performed during radiologic interventions. c) Includes general, cardiothoracic, maxillary, plastic, and orthopedic surgery and neurosurgery. d) Includes allergology, cardiology, geriatrics, general internal medicine, pulmonology, gastroenterology, and rheumatology

a) Includes scintigraphy and PET with and without concomitant CT. b) Includes conventional radiography, dual-energy x-ray absorptiometry, fluoroscopy, and radiography performed during radiologic interventions. c) Includes general, cardiothoracic, maxillary, plastic, and orthopedic surgery and neurosurgery. d) Includes allergology, cardiology, geriatrics, general internal medicine, pulmonology, gastroenterology, and rheumatology. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Radiology Imaging | August 14, 2020
August 14, 2020 — According to ARRS' ...
Tau (blue) and amyloid (orange) distribution patterns for super-agers, normal-agers and MCI patients, when compared to a group of younger, healthy, cognitively normal, amyloid-negative individuals. Brain projections are depicted at an uncorrected significance level of p < .0001. Color bars represent the respective t-statistic. Image courtesy of Merle C. Hoenig, Institute for Neuroscience and Medicine II - Molecular Organization of the Brain, Research Center Juelich, Juelich, Germany, and Department of Nucle

Tau (blue) and amyloid (orange) distribution patterns for super-agers, normal-agers and MCI patients, when compared to a group of younger, healthy, cognitively normal, amyloid-negative individuals. Brain projections are depicted at an uncorrected significance level of p < .0001. Color bars represent the respective t-statistic. Image courtesy of Merle C. Hoenig, Institute for Neuroscience and Medicine II - Molecular Organization of the Brain, Research Center Juelich, Juelich, Germany, and Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.

News | PET Imaging | July 16, 2020
July 16, 2020 — Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have b
PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in keeping with the known tumor recurrence in the prostate. Right: PET shows extensive, intensely PSMA-avid local recurrence in prostate (top row; solid arrow) and a solitary bone metastasis in left rib 2 (bottom row; dotted arrow). Image courtesy of Ur Metser, et al.

PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in keeping with the known tumor recurrence in the prostate. Right: PET shows extensive, intensely PSMA-avid local recurrence in prostate (top row; solid arrow) and a solitary bone metastasis in left rib 2 (bottom row; dotted arrow). Image courtesy of Ur Metser, et al.

News | PET-CT | July 16, 2020
July 16, 2020 — New research confirms the high impact of...
Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared to a typical clinical standardized uptake value image (b), the parametric image of FDG influx rate (Ki) can achieve higher lesion-to-background (e.g., the liver) contrast. In addition to glucose metabolism imaging by Ki, total-body dynamic PET also enables multiparametric characterization of tumors and organs

Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared to a typical clinical standardized uptake value image (b), the parametric image of FDG influx rate (Ki) can achieve higher lesion-to-background (e.g., the liver) contrast. In addition to glucose metabolism imaging by Ki, total-body dynamic PET also enables multiparametric characterization of tumors and organs using additional physiologically important parameters, for example, glucose transport rate K1 (d), across the entire body. Image courtesy of G.B. Wang, M. Parikh, L. Nardo, et al., University of California Davis, Calif.

News | PET Imaging | July 16, 2020
July 16, 2020 — Results from the first...
Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

News | PET Imaging | July 15, 2020
July 15, 2020 — A first-in-human study presented at the Society of...